NCT07069335View on ClinicalTrials.gov

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

May 15, 2026

Study Completion Date

May 15, 2026

Conditions
Ovarian Cancer
Interventions
DRUG

Olaparib 150 MG

Subjects receive 600 mg per day, two tablets BID (total 4 tablets), oral administration

Trial Locations (1)

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY